openPR Logo
Press release

Lung Cancer Therapeutics Market 2018 Global Analysis,Research,Review,Applications and Forecast to 2023

01-11-2018 01:47 PM CET | Health & Medicine

Press release from: WiseGuy Research Consultants Pvt. Ltd.

/ PR Agency: WiseGuy Research Consultants Pvt. Ltd.
Lung Cancer Therapeutics 2018

Lung Cancer Therapeutics 2018

WiseGuyReports.Com adds “Lung Cancer Therapeutics Market 2018 Global Analysis,Research,Review,Applications and Forecast to 2023” Research to its Database.

Description:

Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.

Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the lung cancer therapeutics market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of lung cancer therapeutics market.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/2753929-lung-cancer-therapeutics-market-2012-to-2023

For more information or any query mail at sales@wiseguyreports.com

Lung cancer therapeutics market segmented based on the treatment type, disease type, and end user

Based on the drug type, lung cancer therapeutics market segmented into the following:
Chemotherapy
Taxol
Navelbine
Alimta
Cisplatin
Camptosar
Others
Targeted therapy
Gilotrif
Tarceva
Avastin
Iressa
Others

Based on the disease type, lung cancer therapeutics market segmented into the following:
Small cell lung cancer
Non-small cell lung cancer
Large carcinoid tumour

Based on the end user, lung cancer therapeutics market segmented into the following:
Hospitals
Oncology Clinics
Ambulatory surgical centres

Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the lung cancer therapeutics market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small cell lung cancer.

Geographically, Lung cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America lung cancer therapeutics market is growing due to increase in the prevalence of lung cancer majorly in U.S. (according to CDC 2014, about 215,951 people diagnosed with lung cancer and 155,526 people died of the lung cancer). In addition, increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the lung cancer therapeutics market in North America. In Europe region, rise in the prevalence of lung cancer majorly in Hungary, Serbia, U.K and other Europe countries (according to Cancer Research UK, about 46,403 new lung cancer in the UK and 35,895 people died of the disease), rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the lung cancer therapeutics market. Asia Pacific region is exhibiting significant growth in lung cancer therapeutics market owing to rapid industrialization and availability of low-cost generic products in the region.

Some of the players in lung cancer therapeutics market are Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.), AstraZeneca (U.S.), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), Takeda Pharmaceuticals Co. Ltd. (Japan), Abbvie, Inc. (U.S.), VisionGate, Inc. (U.S.), and Asterias Biotherapeutics (Biotime) (U.S.) to name a few.

In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer
In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer

Ask Query @ https://www.wiseguyreports.com/enquiry/2753929-lung-cancer-therapeutics-market-2012-to-2023

Table Of Contents – Major Key Points

1. Executive summary

2. Global Lung Cancer Therapeutics Market Introduction
2.1. Global Lung Cancer Therapeutics Market – Taxonomy
2.2. Global Lung Cancer Therapeutics Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel

3. Global Lung Cancer Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Lung Cancer Therapeutics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Lung Cancer Therapeutics Market – Pipeline Analysis

4. Global Lung Cancer Therapeutics Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. Global Lung Cancer Therapeutics Market, By Drug Class, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Chemotherapy
5.1.1.1. Taxol
5.1.1.2. Navelbine
5.1.1.3. Alimta
5.1.1.4. Cisplatin
5.1.1.5. Camptosar
5.1.1.6. Others
5.1.2. Targeted therapy
5.1.2.1. Gilotrif
5.1.2.2. Tarceva
5.1.2.3. Avastin
5.1.2.4. Iressa
5.1.2.5. Others
5.1.3. Market Opportunity Analysis

6. Global Lung Cancer Therapeutics Market Forecast, By Disease Type, 2012 - 2016 and Forecast, 2017 - 2023
6.1. Small Cell Lung Cancer
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Non-Small Cell Lung Cancer
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Large Carcinoid Tumor
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7. Market Opportunity Analysis Global Lung Cancer Therapeutics Market Forecast, By End User, 2012 - 2016 and Forecast, 2017 - 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Oncology Clinics
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis

Continue…….

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2753929

For more information or any query mail at sales@wiseguyreports.com

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Office No.528,Amanora Chambers,Magarpatta Road,Hadapsar,Pune-411028.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lung Cancer Therapeutics Market 2018 Global Analysis,Research,Review,Applications and Forecast to 2023 here

News-ID: 896356 • Views: 224

More Releases from WiseGuy Research Consultants Pvt. Ltd.

Surveillance 2018 Global Market Net Worth US$ 43600 million Forecast By 2022
WiseGuyReports.Com Publish a New Market Research Report On –“ Surveillance 2018 Global Market Net Worth US$ 43600 million Forecast By 2022”. Description: The Surveillance industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Surveillance market size to maintain the average annual growth rate of 11.54% from 17980 million $ in 2014 to 24950 million $ in 2017, The analysts believe that in the
Tunnel Boring Machine (TBM) Market 2018 Global Analysis By Key Players – Herre …
WiseGuyReports.Com Publish a New Market Research Report On –“ Tunnel Boring Machine (TBM) Market 2018 Global Analysis By Key Players – Herrenknecht, CRTG, CRCHI, Robbins, Tianhe, Komatsu, Mitsubishi”. Description: The Tunnel Boring Machine (TBM) industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Tunnel Boring Machine (TBM) market size to maintain the average annual growth rate of 7.11% from 1880 million $ in
Ultra Fine Copper Powder 2018 Global Market Net Worth US$ 405 million Forecast B …
WiseGuyReports.Com Publish a New Market Research Report On –“ Ultra Fine Copper Powder 2018 Global Market Net Worth US$ 405 million Forecast By 2022”. Description: The Ultra Fine Copper Powder industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Ultra Fine Copper Powder market size to maintain the average annual growth rate of 5.27% from 270 million $ in 2014 to 315 million
Car Leasing Market 2018 Global Share,Trend,Segmentation and Forecast to 2022
WiseGuyReports.Com Publish a New Market Research Report On –“ Car Leasing Market 2018 Global Share,Trend,Segmentation and Forecast to 2022”. Description: The Car Leasing industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Car Leasing market size to maintain the average annual growth rate of X% from XXXX million $ in 2013 to XXXX million $ in 2016, The analysts believe that in the

All 5 Releases


More Releases for Lung

Non Small Cell Lung Cancer Therapeutics Market
The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled 'Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,' the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026. Fortune Business Insights has
Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018
Interstitial lung disease is a type of inflammatory disease that affects and thickens the interstitium of the lungs. Download the sample report @ https://www.pharmaproff.com/request-sample/1126 The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues. Get the detailed analysis @ https://www.pharmaproff.com/report/interstitial-lung-disease-therapeutics-pipeline-analysis Some of the types of the condition include
Lung Cancer and Therapies Meet 2019
Lexis is the world best platform for all the researchers to showcase their on-going research work through Oral/Poster presentations in front of the international audience, provided with additional opportunities for expanding their research work by conducting workshops and by exhibiting products. It gives you the global exposure and helps to associate with the present and potential researchers who discover novel techniques to treat Lung Cancer with different approach. This meet enlightens
Acute Lung Injury Market Technological breakthroughs 2025
Acute lung injury (ALI) is commonly characterized by hypoxia, lung complication and pulmonary edema. This condition causes inflammation or direct injury to the lungs. Generally, the symptoms of this disease are divided into two forms namely, primary ALI and secondary ALI. Primary ALI is caused by the conditions like pneumonia. While, secondary ALI is mainly caused by indirect injury to the lungs. Inhalation injury, pulmonary contusions, sever trauma, shock are
Lung Cancer Treatment Market Outlook to 2022
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions The global lung cancer drugs market was valued at $3.1bn in 2016 and is forecast to grow at a healthy 31.1% CAGR between 2016
Europe Lung Cancer Drug Pipeline Analysis
The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts